News | August 18, 2025
European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Rivaroxaban is used to treat venous thromboembolism
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Reinforcing commitment to ethical and sustainable growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The agreement complements other PPAs for Sandoz production sites globally
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
This will be Aster’s fifth hospital in Bengaluru
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Subscribe To Our Newsletter & Stay Updated
